IOP remained reduced in patients given loteprednol etabonate suspension 0.5% after canaloplasty, with or without cataract surgery, according to a study.
The retrospective chart review was conducted at Dean McGee Eye Institute, University of Oklahoma. Data were collected for 204 patients who underwent canaloplasty with or without cataract surgery, with 58 undergoing surgery in both eyes on separate days. Nearly 92% of eyes were diagnosed with primary open-angle glaucoma with or without nuclear sclerotic cataract at the time of surgery.
The most frequent dosing regimens of loteprednol etabonate
Uncategorized